Pirfenidone
In the US, Pirfenidone (pirfenidone systemic) is a member of the drug class miscellaneous uncategorized agents and is used to treat Idiopathic Pulmonary Fibrosis.
US matches:
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
L04AX05
CAS registry number (Chemical Abstracts Service)
0053179-13-8
Chemical Formula
C12-H11-N-O
Molecular Weight
185
Therapeutic Categories
Anti-inflammatory agent
Antifibrotic agent
Treatment of idiopathic pulmonary fibrosis
Chemical Names
5-Metyl-1-phenyl-1-H-pyridin-2-one (JAN)
5-Metyl-1-phenyl-2(1H)-pyridone (WHO, USAN)
Foreign Names
- Pirfenidonum (Latin)
- Pirfenidon (German)
- Pirfénidone (French)
- Pirfenidona (Spanish)
Generic Names
- Pirfenidone (OS: USAN, JAN, BAN)
- AMR-69 (IS)
- S-7701 (IS)
Brand Names
- Esbriet
InterMune, Austria; InterMune, Belgium; InterMune, Denmark; InterMune, Spain; InterMune, Finland; InterMune, Lithuania; InterMune, Norway; InterMune, Poland; InterMune, United States; InterMune Canada, Canada; InterMune Nordics, Sweden; Roche, Germany; Roche, France; Roche, Croatia (Hrvatska); Roche, Ireland; Roche, Iceland; Roche, Slovenia; Roche Products, United Kingdom - Pirespa
Shionogi Seiyaku, Japan
Glossary
| Term | Definition |
|---|---|
| BAN | British Approved Name |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
